| Autor: |
Kolachala VL; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA., Wei C; Division of Rheumatology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.; Department of Medicine, Lowance Center for Human Immunology, Atlanta, GA, USA.; Department of Medicine, Emory Autoimmunity Center of Excellence, Atlanta, GA, USA., Venkateswaran S; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA., Hill AL; Division of Rheumatology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.; Department of Medicine, Lowance Center for Human Immunology, Atlanta, GA, USA.; Department of Medicine, Emory Autoimmunity Center of Excellence, Atlanta, GA, USA., Warren V; Division of Rheumatology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.; Department of Medicine, Lowance Center for Human Immunology, Atlanta, GA, USA.; Department of Medicine, Emory Autoimmunity Center of Excellence, Atlanta, GA, USA., Espinoza H; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Pediatric Transplant, Children's Healthcare of Atlanta, Transplant Services, Atlanta, GA, USA., Sanz I; Division of Rheumatology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.; Department of Medicine, Lowance Center for Human Immunology, Atlanta, GA, USA.; Department of Medicine, Emory Autoimmunity Center of Excellence, Atlanta, GA, USA., Gupta NA; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Pediatric Transplant, Children's Healthcare of Atlanta, Transplant Services, Atlanta, GA, USA. |
| Abstrakt: |
Autoimmune hepatitis (AIH) is a chronic, inflammatory liver disease of unknown aetiology which requires lifelong immunosuppression. Most therapeutic and outcome studies of AIH have been conducted predominantly in Caucasian (European Ancestry, EA) cohorts, with the exclusion of African American (AA) patients due to inadequate sample size. It is known that AA patients have a severe phenotype of autoimmune diseases and demonstrate a poor response to conventional medical therapy. Understanding cellular and molecular pathways which determine AIH severity and progression in AA patients is likely to lead to the discovery of novel, personalised and better tolerated therapies. The aim of the study is to determine the distinct effector B cell phenotypes which contribute to disease severity and progression of AIH in AA children as compared to their EA cohorts. PBMCs were isolated from blood samples collected from patients visiting Children's Healthcare of Atlanta (CHOA) and were grouped into AA, ( n = 12), EA, ( n = 11) and controls ( n = 12) and were processed for flow cytometry. Markers of B cell development, maturation and activation were assessed namely CD19, CD21, IgD, CD27, CD38, CD11c, CD24, CD138. AA children with AIH demonstrated an expansion of CD19 + ve, Activated Naïve (aN), (CD19 + IgD - /CD27 - Double Negative (DN 2 ) ([CD19+/IgD - /CD27 ++ CD38 ++ ) cells. Plasmablasts were significantly higher along with Signalling Lymphocytic activation molecule F7 (SLAMF7). Unswitched memory [CD19+] IgD + CD27 + (USM) B cells were significantly contracted in AA patients with AIH. B cell phenotyping reveals a distinct profile in AA AIH patients with a major skewing towards the expansion of effector pathways which have been previously characterised in severe SLE in AA patients. These results suggest that the quantification and therapeutic target of B cell pathway could contribute substantially to the clinical approach to AIH especially in the AA population. |
